Correlation of Metabolic Syndrome and Low-level High-density Lipoprotein Cholesterol with Adverse Pathological Features of Prostate Cancer After Radical Prostatectomy
-
摘要:目的
探究代谢综合征(MetS)及低水平高密度脂蛋白胆固醇(HDL-C)与根治性前列腺切除术(RP)后前列腺癌(PCa)侵袭性的相关性。
方法收集232例接受RP的PCa患者的各项生理指标并进行前瞻性多中心研究。将伴有MetS的患者设为MetS组(MetS), 无MetS的患者设为非MetS组(No MetS)。MetS按照NCEP-ATP Ⅲ进行评估。局部晚期PCa为pT-分期≥3;采用Gleason评分系统进行病理分级; MetS及其各项指征与病理特征的相关性采用回归分析进行评估。
结果MetS是RP术后Gleason评分≥8的独立风险因素。低水平HDL-C与局部晚期PCa相关。随着患者出现MetS指征数目增多, 出现不良病理特征的风险增加。
结论低水平HDL-C和具备4个及以上MetS指征分别与更高风险的PCa不良病理特征相关。
Abstract:ObjectiveTo assess the association of metabolic syndrome (MetS) and low-level high density lipoprotein-cholesterol (HDL-C) with the invasion of prostate cancer (PCa) in the patients after radical prostatectomy (RP).
MethodsWe collected and analyzed the data of 232 PCa patients treated with RP for prospective multicenter clinical study.The MetS was assessed according to NCEP-ATP Ⅲ.Patients were divided into MetS group and non-MetS group.Locally advanced PCa was defined as a pT-stage≥3.ISUP Gleason grading system (GS) were used for pathological grading.Logistic regression analyses assessed the association of MetS and its components with pathological data.
ResultsMetS was an independent risk factor for GS≥8 after RP.Low HDL-C level was associated with locally advanced PCa.The risks of adverse pathological features increased with the number of MetS components.
ConclusionLow HDL-C level and 4 or more MetS components are associated with higher risk of adverse pathological features of PCa.
-
Key words:
- Metabolic syndrome /
- HDL-C /
- Prostate cancer /
- Radical prostatectomy
-
Competing interests: The authors declare that they have no competing interests.作者贡献：韩俊岭：执行实验、整理分析数据、撰写文章陈昆：提供病理阅片资料翟晓磊、韩前河：病理技术操作单中杰：论文指导
-
表 1 232例前列腺癌患者术前基本信息
Table 1 Preoperative basic characteristics of 232 prostate cancer (PCa) patients
下载: 导出CSV
表 2 232例前列腺癌患者术前分级与分期
Table 2 Preoperative pathological grading and staging of 232 prostate cancer patients
下载: 导出CSV
表 3 侵袭性PCa病理特征与术前因素相关性
Table 3 Correlation between pathological features of aggressive PCa and preoperative factors
下载: 导出CSV
表 4 MetS指征与侵袭性PCa病理特征的相关性
Table 4 Correlation between MetS components and pathological features of aggressive PCa
下载: 导出CSV
表 5 MetS指征数目与侵袭性PCa病理特征的相关性
Table 5 Correlation between number of MetS components and pathological features of aggressive PCa
下载: 导出CSV
-
[1] Saklayen MG. The Global Epidemic of the Metabolic Syndrome[J]. Curr Hypertens Rep, 2018, 20(2): 12. doi: 10.1007/s11906-018-0812-z
[2] 梁桐, 刘华杰, 达明绪. 代谢综合征与胃癌发病风险的Meta分析[J]. 肿瘤防治研究, 2021, 48(3): 268-273. doi: 10.3971/j.issn.1000-8578.2021.20.0957 [Liang T, Liu HJ, Da MX. Metabolic Syndrome and Risk of Gastric Cancer: A Meta-analysis[J]. Zhong Liu Fang Zhi Yan Jiu, 2021, 48(3): 268-273. ] doi: 10.3971/j.issn.1000-8578.2021.20.0957
[3] Dawson JK, Dorff TB, Todd Schroeder E, et al. Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial[J]. BMC cancer, 2018, 18(1): 368. doi: 10.1186/s12885-018-4306-9
[4] Hammarsten J, Damber JE, Haghsheno MA, et al. A stage-dependent link between metabolic syndrome components and incident prostate cancer[J]. Nat Rev Urol, 2018, 15(5): 321-333. doi: 10.1038/nrurol.2018.8
[5] Schatten H. Brief Overview of Prostate Cancer Statistics, Grading, Diagnosis and Treatment Strategies[J]. Adv Exp Med Biol, 2018, 1095: 1-14.
[6] 韩俊岭, 陈昆, 马杰锋, 等. 沉默LMTK2对去势抵抗性前列腺癌PC3细胞增殖的影响[J]. 中国肿瘤, 2019, 28(1): 63-68. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU201901010.htm [Han JL, Chen K, Ma JF, et al. The effect of silencing LMTK2 on the proliferation of castration-resistant prostate cancer PC3 cells[J]. Zhongguo Zhong Liu, 2019, 28(1): 63-68. ] https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU201901010.htm
[7] Caliskan S, Kaba S, Özsoy E, et al. The effect of metabolic syndrome on prostate cancer final pathology[J]. J Cancer Res Ther, 2019, 15(Supplement): S47-S50.
[8] De Nunzio C, Brassetti A, Simone G, et al. Metabolic syndrome increases the risk of upgrading and upstaging in patients with prostate cancer on biopsy: a radical prostatectomy multicenter cohort study[J]. Prostate Cancer Prostatic Dis, 2018, 21(3): 438-445. doi: 10.1038/s41391-018-0054-9
[9] Liu W, Li W, Wang Z, et al. Metabolically Abnormal Obesity Increases the Risk of Advanced Prostate Cancer in Chinese Patients Undergoing Radical Prostatectomy[J]. Cancer Manag Res, 2020, 12: 1779-1787. doi: 10.2147/CMAR.S242193
[10] Morlacco A, Dal Moro F, Rangel LJ, et al. Impact of metabolic syndrome on oncologic outcomes at radical prostatectomy[J]. Urol Oncol, 2018, 36 (12): 528. e1-528. e6. doi: 10.1016/j.urolonc.2018.10.003
[11] Epstein JI, Amin MB, Fine SW, et al. The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer[J]. Arch Pathol Lab Med, 2021, 145 (4): 461-493. doi: 10.5858/arpa.2020-0015-RA
[12] Bhindi B, Xie WY, Kulkarni GS, et al. Influence of metabolic syndrome on prostate cancer stage, grade, and overall recurrence risk in men undergoing radical prostatectomy[J]. Urology, 2016, 93: 77-85. doi: 10.1016/j.urology.2016.01.041
[13] De Nunzio C, Simone G, Brassetti A, et al. Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatec- tomy: results from a multicentre prospective study[J]. BMC Cancer, 2016, 16: 407. doi: 10.1186/s12885-016-2442-7
[14] Pandey M, Cuddihy G, Gordon JA, et al. Inhibition of Scavenger Receptor Class B Type 1 (SR-B1) Expression and Activity as a Potential Novel Target to Disrupt Cholesterol Availability in Castration-Resistant Prostate Cancer[J]. Pharmaceutics, 2021, 13 (9): 1509. doi: 10.3390/pharmaceutics13091509
[15] Salgado-Montilla J, Soto Salgado M, Surillo Trautmann B, et al. Association of serum lipid levels and prostate cancer severity among Hispanic Puerto Rican men[J]. Lipids Health Dis, 2015, 14: 111. doi: 10.1186/s12944-015-0096-0
[16] Kumar N, Mandal CC. Cholesterol-Lowering Drugs on Akt Signaling for Prevention of Tumorigenesis[J]. Front Genet, 2021, 12: 724149.
[17] Sourbeer KN, Howard LE, Andriole GL, et al. Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study[J]. BJU Int, 2015, 115(5): 736-743. doi: 10.1111/bju.12843
[18] De Nunzio C, Presicce F, Lombardo R, et al. Physical activity as a risk factor for prostate cancer diagnosis: a prospective biopsy cohort analysis[J]. BJU Int, 2016, 117(6B): E29-35.
计量
- 文章访问数: 1702
- HTML全文浏览量: 559
- PDF下载量: 282
